Potential of moclobemide to improve cerebral insufficiency identified using a scopolamine model of aging and dementia

@article{Wesnes1990PotentialOM,
  title={Potential of moclobemide to improve cerebral insufficiency identified using a scopolamine model of aging and dementia},
  author={Keith A Wesnes and R Anand and Thomas Lorscheid},
  journal={Acta Psychiatrica Scandinavica},
  year={1990},
  volume={82}
}
After a baseline performance assessment, 28 healthy male volunteers received subcutaneous injections of scopolamine hydrobromide to induce deficits in memory, attention and cognitive processes. Subsequent performance testing established the decrements caused by the scopolamine, and then each subject was given one of 3 investigational drugs including moclobemide, or placebo, according to a latin‐square design. Parallel versions of the test procedures were used to assess drug effects on the… Expand
Effects of the cholinomimetic SDZ ENS-163 on scopolamine-induced cognitive impairment in humans.
TLDR
50 mg of oral SDZ ENS-163 has cholinomimetic activity in normal men, but this dose is insufficient to reverse the muscarinic effects of 0.4 mg of intravenous scopolamine. Expand
Cognition Enhancers in Age-Related Cognitive Decline
TLDR
There is no cognition enhancer that has reliably and repeatedly been demonstrated to be efficacious for the treatment of AACD, however, this situation may change as the selectivity, specificity and adverse effect profiles of substances that are being developed for the Treatment of AD may be expected to be improved in the future. Expand
From transmitters to treatment: the pharmacotherapy of behavioural disturbances in dementia.
  • N. Herrmann, K. Lanctôt
  • Psychology, Medicine
  • Canadian journal of psychiatry. Revue canadienne de psychiatrie
  • 1997
TLDR
This paper reviews recent studies that examine the neurochemical basis of behavioural disturbances in dementia to determine whether transmitter-specific or behavioural-specific targeted interventions truly provide a rationale for the effective pharmacotherapy of these disorders. Expand
Cognitive and Psychomotor Effects of Antidepressants with Emphasis on Selective Serotonin Reuptake Inhibitors and the Depressed Elderly Patient
Cognitive and psychomotor impairment are important considerations in the treatment of depression in the elderly due to both the underlying slowing of cognitive and psychomotor processes as a normalExpand
The Depressions of Alzheimer's Disease: Sorting, Pharmacotherapy, and Clinical Advice
  • D. Knesper
  • Psychology, Medicine
  • Journal of geriatric psychiatry and neurology
  • 1995
TLDR
Evidence for efficacy in controlled trials is weak, but open-label trials are, as expected, more encouraging, and a heuristic model provides a rational basis for thinking about medication selection for AD depressions. Expand
Neuroprotective Effect of Ellagic Acid Against Chronically Scopolamine Induced Alzheimer ' s Type Memory and Cognitive Dysfunctions : Possible Behavioural and Biochemical Evidences
Adjudge the neuroprotective ability of Ellagic acid (EA) as a constructive herbal drug to impede cholinergic dysfunctions and oxidative stress in Alzheimer’s disease (AD) in chronically administeredExpand
Effects of sibutramine alone and with alcohol on cognitive function in healthy volunteers.
TLDR
There was little evidence of a clinically relevant interaction of sibutramine with the impairment of cognitive function produced by alcohol in healthy volunteers and the single statistically significant interaction indicated a reduction, rather than a worsening, of alcohol-induced impairment when sibUTramine is taken concomitantly. Expand
Human models as tools in the development of psychotropic drugs
TLDR
An R α D program aimed to adapt existing models and develop new paradigms suitable for early proof of concept substantiation of central nervous system drug development, with a focus on psychiatric disorders. Expand
Effects of N-propargyl-1-(R)aminoindan (rasagiline) in models of motor and cognition disorders.
TLDR
Racemic N-propargyl-1-aminoindan (AGN-1135), besides being of lower potency, had a different dose-dependency than rasagiline in antagonizing haloperidol-induced catalepsy or alpha-MpT-induced hypokinesia, and produced effects that were distinct in certain respects from those of rasgiline. Expand
Avoiding and Managing Anticholinergic Effects of Antidepressants
TLDR
It is argued that for this reason, prescription of the classical tricyclic antidepressants should be avoided in elderly depressed patients and the second generation, or atypical antidepressants, and the newer selective serotonin (5-hydroxytryptamine; 5-HT) reuptake inhibitors (SSRIs) are considered to be useful alternatives in elderly patients. Expand
...
1
2
3
...